Differential Expression of CD43, CD81, and CD200 in Classic Versus Variant Hairy Cell Leukemia

Abstract

Background Hairy cell leukemia (HCL) and hairy cell leukemia variant (HCLv) are rare diseases with overlapping clinicopathological features. Features distinguishing HCL from HCLv include expression of CD25, CD123, CD200, annexin‐A1, and the presence of BRAF V600E mutation. HCLv typically lacks these markers, but they may occur in a subgroup of HCL patients with an aggressive clinical course. We examined CD43, CD81, CD79b, and CD200 expression in HCL and HCLv. Methods Multiparametric flow cytometry (FCM) was performed on blood from 59 HCL and 15 HCLv patients for protocol entry. Mean fluorescent intensity (MFI) of CD43, CD79b, CD81, and CD200 was determined (for CD200, n = 17 and 7, respectively). Results Median MFI of HCL vs HCLv was 545 vs 272 for CD43, 602 vs 2,450 for CD81, 4,962 vs 1,969 for CD79b, and 11,652 vs 1,405 for CD200, respectively. Analysis of the median differences, HCL minus HCLv (and their 95% confidence intervals and P‐values) indicated that CD43 MFI (estimated median difference (95% CI): 212 [72–413; P = 0.0027) and CD200 MFI (9,883 [3,514–13,434]; P < 0.0001) were higher in HCL than in HCLv, while CD81 MFI (−1,858 [−2,604 to −1,365]; P < 0.0001) was lower in HCL than in HCLv. CD79b MFI HCL median was more than double that of HCLv, but the observed difference (1,571 [−739 to 4,417]) was consistent with the null hypothesis of no difference (P = 0.13). Conclusions CD200, CD43, and CD81 are likely differentially expressed between HCL and HCLv, reflecting their differing disease biology. Inclusion of these markers in FCM is potentially informative. © 2019 International Clinical Cytometry Society

Increased expression of CD81 is associated with poor prognosis of prostate cancer and increases the progression of prostate cancer cells in�vitro

“…CD81 was considered to function as an oncogene in prostate cancer. Previous studies have revealed differential expression of CD81 in various types of cancers, such as classic vs. variant hairy cell leukemia, breast cancer, and gastric cancer (13,27,28). A study by Vences-Catalan et al indicated that CD81, which is a promoter of tumor growth and metastasis, is widely expressed in most tissues and on the majority of tumor cells (11).…”

Hairy cell leukemia: 2020 update on diagnosis, risk stratification, and treatment

“…The HCL immunological score is low (0 or 1): there is no expression of CD25 and CD200. CD123 expression is inconstant and weak . Note, SDRPL, also a provisional entity, is different from HCL‐V.…”

Flow cytometry in the diagnosis of mature B‐cell lymphoproliferative disorders

“…Cells are morphologically more difficult to identify but are often characterized by the presence of a prominent nucleolus and display a variant immunophenotype including the absence of CD25 and CD123 . Moreover, CD43, CD81, and CD200 have been reported as able to discriminate both HCL types …”